News from GlycoVaxyn AG A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

01 Jul, 2014, 02:00 ET GlycoVaxyn announces the initiation of a Phase I clinical trial in collaboration with Janssen for a vaccine against Extra-intestinal pathogenic Escherichia coli causing urinary tract infection

GlycoVaxyn AG, a leader in the development of innovative conjugate vaccines, today announced the initiation of a Phase 1 clinical trial of a...


29 Jul, 2013, 07:00 ET GlycoVaxyn AG secures CHF 5.1 million Strategic Translation Award from the Wellcome Trust to finance clinical development of Shigella vaccine

 Following recently signed collaborations with GlaxoSmithKline Biologicals (GSK) and Janssen Pharmaceuticals (JPI), GlycoVaxyn AG, a leader in...


06 Mar, 2013, 08:55 ET GlycoVaxyn AG anuncia la adición de Gerd Zettlmeissl como presidente del consejo de dirección

Tras las recientes colaboraciones firmadas con GlaxoSmithKline Biologicals y Janssen Pharmaceuticals, GlycoVaxyn AG, líder en el desarrollo de...


06 Mar, 2013, 02:00 ET GlycoVaxyn AG announces Addition of Gerd Zettlmeissl, as Chairman of the Board of Directors

 Following recently signed collaborations with GlaxoSmithKline Biologicals and Janssen Pharmaceuticals, GlycoVaxyn AG, a leader in the...


06 Mar, 2013, 02:00 ET La société de biotechnologie Suisse GlycoVaxyn SA annonce la nomination de Gerd Zettlmeissl à la direction du Conseil d'Administration

 Après la signature de deux collaborations avec GlaxoSmithkline et Janssen Pharmaceuticals, GlycoVaxyn SA, pionnier dans le...


06 Mar, 2013, 02:00 ET GlycoVaxyn AG ergänzt seinen Verwaltungsrat und ernennt Gerd Zettlmeissl zum Verwaltungsratspräsidenten

 Nach den kürzlich angekündigten Kollaborationen mit GlaxoSmithKline Biologicals und Janssen Pharmaceuticals gibt GlycoVaxyn AG, ein...


04 Jan, 2013, 11:10 ET GlycoVaxyn AG Signs Exclusive License Agreement and Enters Research and Development Collaboration with Janssen Pharmaceuticals, Inc., to Develop Multi-Valent Bacterial Vaccine

 GlycoVaxyn AG, a leader in the development of innovative vaccines, today announced that Janssen Pharmaceuticals, Inc. (JPI), has signed an...


19 Dec, 2012, 07:00 ET GlycoVaxyn AG Announces Strategic Collaboration with GSK to Develop New Bacterial Vaccines using GlycoVaxyn's Bio-Conjugation Technology

 GlycoVaxyn AG, a leader in the development of innovative vaccines, today announced a collaboration with GlaxoSmithKline Biologicals (GSK) to...


19 Dec, 2012, 07:00 ET GlycoVaxyn AG schliesst eine strategische Zusammenarbeit zur Entwicklung neuer bakterieller Impfstroffe mit GSK ab, welche auf GlycoVaxyn's Bio-Konjugationstechnologie basiert

GlycoVaxyn AG, ein führendes Biotechunternehmen in der Entwicklung innovativer Impfstoffe hat heute eine Zusammenarbeit mit GlaxoSmithKline...


16 Sep, 2011, 03:00 ET GlycoVaxyn's Staphylococcus aureus Bioconjugate Vaccine Candidate Protects Mice Against Invasive S. aureus Infection

GlycoVaxyn AG, a leader in the development of innovative vaccines, today announced an abstract to be presented on a glycoprotein vaccine based on...


15 Jun, 2011, 19:54 ET GlycoVaxyn veranstaltet zweiten jährlichen Wissenschaftstag zu Herausforderungen und Chancen im Bereich der Impfstoffentwicklung

    GlycoVaxyn AG, ein im Bereich der Entwicklung konjugierter Impfstoffe führendes Unternehmen, gab heute bekannt, es werde seinen...


15 Jun, 2011, 19:52 ET GlycoVaxyn s'apprête à accueillir la deuxième Journée annuelle de la Science pour discuter des défis et des opportunités en matière de développement de vaccins

    GlycoVaxyn AG, un chef de file dans le développement de vaccins conjugués, a aujourd'hui annoncé l'organisation de sa...


15 Jun, 2011, 05:00 ET GlycoVaxyn to Host Second Annual Science Day to Discuss Challenges and Opportunities in Vaccine Development

GlycoVaxyn AG, a leader in the development of conjugate vaccines, today announced that it will host its Second Annual Science Day to discuss...


05 Mar, 2009, 03:05 ET GlycoVaxyn AG Raises CHF 25 Million in Financing Led by Edmond de Rothschild Investment Partners

- Proceeds to Facilitate Clinical Development of Lead Conjugate Vaccine GlycoVaxyn, a pioneer in the development of innovative...


20 May, 2008, 01:00 ET GlycoVaxyn Appoints Philippe Dro as CEO

ZURICH-SCHLIEREN, Switzerland, May 20 /PRNewswire/ -- GlycoVaxyn AG, a pioneer in glycoengineering primarily developing innovative conjugated...